FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Madelaine Wohlreich

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Double-Blind Method

Devices

Placebos

Co-author Network

Publications

TOP 3
Paula J Gaynor; Peng Liu; Mary A Weller; Madelaine M Wohlreich
Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions.
Ronald C Wielage; Madelaine M Wohlreich; J Scott Andrews; Megha Bansal; Robert W Klein; Michael Happich
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.
Rebecca L Robinson; David A Williams; Madelaine M Wohlreich; Philip Mease; Yi Chen; Deborah D'Souza; Kurt Kroenke; Bill McCarberg
Burden of illness and treatment patterns for patients with fibromyalgia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Madelaine Wohlreich (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Paula J Gaynor; Peng Liu; Mary A Weller; Madelaine M Wohlreich
Comparison of safety outcomes among Caucasian, Hispanic, Black, and Asian patients in duloxetine studies of chronic painful conditions.
Current medical research and opinion 2013;29(5):549-60.
2013: Ronald C Wielage; Madelaine M Wohlreich; J Scott Andrews; Megha Bansal; Robert W Klein; Michael Happich
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2013;16(2):334-44.
2012: Rebecca L Robinson; David A Williams; Madelaine M Wohlreich; Philip Mease; Yi Chen; Deborah D'Souza; Kurt Kroenke; Bill McCarberg
Burden of illness and treatment patterns for patients with fibromyalgia.
Pain medicine (Malden, Mass.) 2012;13(10):1366-76.
2012: Richard Mohs; Fujun Wang; Jonna Ahl; Lesley M Arnold; Paula J Gaynor; Philip Mease; Madelaine M Wohlreich
The effect of duloxetine treatment on cognition in patients with fibromyalgia.
Psychosomatic medicine 2012;74(6):628-34.
2011: Elijah P Frakes; Marc C Hochberg; R C Risser; T D Ball; Madelaine M Wohlreich
Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial.
Current medical research and opinion 2011;27(12):2361-72.
2011: Lesley M Arnold; Paula J Gaynor; Fujun Wang; Jonna Ahl; Madelaine M Wohlreich
Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial.
Arthritis research & therapy 2011;13(3):R86.
2011: Lauren B Marangell; Daniel J Clauw; Ernest Choy; Fujun Wang; Scarlett Shoemaker; Laurence Bradley; Philip Mease; Madelaine M Wohlreich
Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine.
Pain 2011;152(1):31-7.
2010: Lesley M Arnold; Daniel J Clauw; Fujun Wang; Jonna Ahl; Paula J Gaynor; Madelaine M Wohlreich
Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.
The Journal of rheumatology 2010;37(12):2578-86.
2010: Laurence A Bradley; Madelaine M Wohlreich; Fujun Wang; Paula J Gaynor; Michael J Robinson; Deborah N D'Souza; Philip J Mease
Pain response profile of patients with fibromyalgia treated with duloxetine.
The Clinical journal of pain 2010;26(6):498-504.
2010: Philip J Mease; Irwin Russell; Daniel K Kajdasz; Curtis G Wiltse; Michael Detke; Madelaine M Wohlreich; Daniel J Walker; Amy S Chappell
Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.
Seminars in arthritis and rheumatism 2010;39(6):454-64.
2010: Laurence A Bradley; Robert Bennett; Irwin Russell; Madelaine M Wohlreich; Amy S Chappell; Fujun Wang; Deborah N D'Souza; Harvey Moldofsky
Effect of duloxetine in patients with fibromyalgia: tiredness subgroups.
Arthritis research & therapy 2010;12(4):R141.
2009: James I Hudson; Lesley M Arnold; Laurence A Bradley; Ernest H S Choy; Philip J Mease; Fujun Wang; Jonna Ahl; Madelaine M Wohlreich
What makes patients with fibromyalgia feel better? Correlations between Patient Global Impression of Improvement and changes in clinical symptoms and function: a pooled analysis of 4 randomized placebo-controlled trials of duloxetine.
The Journal of rheumatology 2009;36(11):2517-22.
2009: Ernest H S Choy; Philip J Mease; Daniel K Kajdasz; Madelaine M Wohlreich; Paul Crits-Christoph; Daniel J Walker; Amy S Chappell
Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.
Clinical rheumatology 2009;28(9):1035-44.
2009: Madelaine M Wohlreich; Mark D Sullivan; Craig H Mallinckrodt; Amy S Chappell; Tina M Oakes; John G Watkin; Joel Raskin
Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis.
Psychosomatics 2009;50(4):402-12.
2009: Lesley M Arnold; James I Hudson; Fujun Wang; Madelaine M Wohlreich; Apurva Prakash; Daniel K Kajdasz; Amy S Chappell
Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
The Clinical journal of pain 2009;25(6):461-8.
2009: Lesley M Arnold; Daniel J Clauw; Madelaine M Wohlreich; Fujun Wang; Jonna Ahl; Paula J Gaynor; Amy S Chappell
Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials.
Primary care companion to the Journal of clinical psychiatry 2009;11(5):237-44.
2008: Robert H Howland; Michael G Wilson; Susan G Kornstein; Anita H Clayton; Madhukar H Trivedi; Madelaine M Wohlreich; Maurizio Fava
Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2008;20(4):209-18.
2008: Lesley M Arnold; Adam L Meyers; Prabha Sunderajan; C Brendan Montano; Ethan Kass; Madhukar Trivedi; Madelaine M Wohlreich
The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2008;20(4):187-93.
2008: Susan G Kornstein; David L Dunner; Adam L Meyers; Virgil G Whitmyer; Craig H Mallinckrodt; Madelaine M Wohlreich; Michael Detke; Millie S Hollandbeck; John H Greist
A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy.
The Journal of clinical psychiatry 2008;69(9):1383-92.
2008: Jonathan Davidson; Christer Allgulander; Mark Pollack; James Hartford; Janelle S Erickson; James M Russell; David Perahia; Madelaine M Wohlreich; Janice Carlson; Joel Raskin
Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.
Human psychopharmacology 2008;23(6):519-26.
2008: Madelaine M Wohlreich; Nayan Acharya; Indiana Strombom; Louis Kuritzky; Michael Robinson; Alexandra N Heinloth; Arie Regev; Joachim F Wernicke
Answers to the most common questions about the hepatic safety profile of duloxetine.
Postgraduate medicine 2008;120(2):111-8.
2008: Irwin Russell; Philip J Mease; Timothy R Smith; Daniel K Kajdasz; Madelaine M Wohlreich; Michael Detke; Daniel J Walker; Amy S Chappell; Lesley M Arnold
Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.
Pain 2008;136(3):432-44.
2008: Timothy Petersen; Roy H Perlis; Chris Ticknor; Jim Lohr; H Brent Solvason; John P O'Reardon; Madelaine M Wohlreich; Charissa Andreotti; Michael Wilson; Maurizio Fava
Efficacy of duloxetine for the treatment of depression: relationship to most recent antidepressant trial.
Psychopharmacology bulletin 2008;41(1):34-45.
2007: Virgil G Whitmyer; David L Dunner; Susan G Kornstein; Adam L Meyers; Craig H Mallinckrodt; Madelaine M Wohlreich; Jill S Gonzales; John H Greist
A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
The Journal of clinical psychiatry 2007;68(12):1921-30.
2007: Richard C Shelton; Anne C Andorn; Craig H Mallinckrodt; Madelaine M Wohlreich; Joel Raskin; John G Watkin; Michael Detke
Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
International clinical psychopharmacology 2007;22(6):348-55.
2007: Richard C Shelton; A Prakash; Craig H Mallinckrodt; Madelaine M Wohlreich; Joel Raskin; M J Robinson; Michael Detke
Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
International journal of clinical practice 2007;61(8):1337-48.
2007: Maurizio Fava; James M Martinez; John H Greist; Lauren B Marangell; Eileen Brown; Lei Chen; Madelaine M Wohlreich
The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2007;19(3):187-95.
2007: Anita Clayton; Susan G Kornstein; Apurva Prakash; Craig H Mallinckrodt; Madelaine M Wohlreich
Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
The journal of sexual medicine 2007;4(4 Pt 1):917-29.
2007: Teresa A Pigott; Apurva Prakash; Lesley M Arnold; Scott Tyler Aaronson; Craig H Mallinckrodt; Madelaine M Wohlreich
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Current medical research and opinion 2007;23(6):1303-18.
2007: Heidi K Moore; Madelaine M Wohlreich; Michael G Wilson; James C Mundt; Maurizio Fava; Craig H Mallinckrodt; John H Greist
Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine.
Psychiatry (Edgmont (Pa. : Township)) 2007;4(3):30-8.
2007: Andrew A Nierenberg; John H Greist; Craig H Mallinckrodt; Apurva Prakash; Angelo Sambunaris; Gary D Tollefson; Madelaine M Wohlreich
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Current medical research and opinion 2007;23(2):401-16.
2007: Madelaine M Wohlreich; Wenyu Ye; Durisala Desaiah; Susan G Kornstein; Kurt Kroenke; Rebecca L Robinson; Curtis G Wiltse; John H Greist
Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study.
Primary care companion to the Journal of clinical psychiatry 2007;9(4):271-9.
2007: Madelaine M Wohlreich; Craig H Mallinckrodt; Apurva Prakash; John G Watkin; William P Carter
Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Depression and anxiety 2007;24(1):41-52.
2006: Roberto Lewis-Fernández; Carlos Blanco; Craig H Mallinckrodt; Madelaine M Wohlreich; John G Watkin; John M Plewes
Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.
The Journal of clinical psychiatry 2006;67(9):1379-90.
2006: Donna E Stewart; Madelaine M Wohlreich; Craig H Mallinckrodt; John G Watkin; Susan G Kornstein
Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
Journal of affective disorders 2006;94(1-3):183-9.
2006: Craig H Mallinckrodt; Apurva Prakash; Anne C Andorn; John G Watkin; Madelaine M Wohlreich
Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
Journal of psychiatric research 2006;40(4):337-48.
2006: Susan G Kornstein; Madelaine M Wohlreich; Craig H Mallinckrodt; John G Watkin; Donna E Stewart
Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
The Journal of clinical psychiatry 2006;67(5):761-70.
2006: Rahn Kennedy Bailey; Craig H Mallinckrodt; Madelaine M Wohlreich; John G Watkin; John M Plewes
Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.
Journal of the National Medical Association 2006;98(3):437-47.
2005: Madelaine M Wohlreich; James M Martinez; Craig H Mallinckrodt; Apurva Prakash; John G Watkin; Maurizio Fava
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Journal of clinical psychopharmacology 2005;25(6):552-60.
2005: Madelaine M Wohlreich; Craig H Mallinckrodt; John G Watkin; Michael G Wilson; John H Greist; Pedro Delgado; Maurizio Fava
Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2005;17(4):259-68.
2005: Vivien K Burt; Madelaine M Wohlreich; Craig H Mallinckrodt; Michael Detke; John G Watkin; Donna E Stewart
Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years.
Psychosomatics 2005;46(4):345-54.
2005: James I Hudson; Madelaine M Wohlreich; Daniel K Kajdasz; Craig H Mallinckrodt; John G Watkin; Oleg V Martynov
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
Human psychopharmacology 2005;20(5):327-41.
2005: J Craig Nelson; Madelaine M Wohlreich; Craig H Mallinckrodt; Michael Detke; John G Watkin; John S Kennedy
Duloxetine for the treatment of major depressive disorder in older patients.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2005;13(3):227-35.
2005: Craig H Mallinckrodt; John G Watkin; Chaofeng Liu; Madelaine M Wohlreich; Joel Raskin
Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
BMC psychiatry 2005;5():1.
2005: Stephen K Brannan; Craig H Mallinckrodt; Eileen B Brown; Madelaine M Wohlreich; John G Watkin; Alan F Schatzberg
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Journal of psychiatric research 2005;39(1):43-53.
2004: Madelaine M Wohlreich; Craig H Mallinckrodt; John G Watkin; Donald P Hay
Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study.
BMC geriatrics 2004;4():11.
2004: Lesley M Arnold; Yili Lu; Leslie J Crofford; Madelaine M Wohlreich; Michael Detke; Smriti Iyengar; David J Goldstein
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arthritis and rheumatism 2004;50(9):2974-84.
2004: Madelaine M Wohlreich; John G Watkin; Jill S Gonzales
Duloxetine's role in the treatment of depression and associated painful physical symptoms.
The Journal of clinical psychiatry 2004;65(7):1018-9.
2004: Maurizio Fava; Craig H Mallinckrodt; Michael Detke; John G Watkin; Madelaine M Wohlreich
The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
The Journal of clinical psychiatry 2004;65(4):521-30.
2004: Craig H Mallinckrodt; Joel Raskin; Madelaine M Wohlreich; John G Watkin; Michael Detke
The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
BMC psychiatry 2004;4():26.
2002: Cherri M Miner; Eileen Brown; Susan McCray; Jill Gonzales; Madelaine M Wohlreich
Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
Clinical therapeutics 2002;24(3):417-33.